JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China | Business Wire

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China | Business Wire





JW Therapeutics buys out a Hong Kong cancer cell therapy developer

Shanghai’s JW Therapeutics has taken over Syracuse Biopharma after acquiring the Hong Kong-based company in a deal that also gives the Juno/Wuxi AppTec joint venture exclusive licensing rights to Eureka’s ARTEMIS antibody T-cell receptor (TCR) and solid tumor technology for China and the ASEAN countries, paving its path into the solid cancers market.

“Syracuse and Eureka have developed an elegant approach to treating solid tumors with their TCR-mimic and ARTEMIS technologies,” James Li, co-founder and CEO of JW Therapeutics, said in a statement.

The terms of the deal weren’t disclosed. But as part of the agreement, Cheng Liu, founded and president of Eureka, will join the board of directors of JW Therapeutics. Speaking to Endpoints News, Liu said his company has focused on solid tumors since licensing out several binding domains to Juno in 2016 when the CAR-T player was developing treatments for multiple myeloma.